KindredBio Announces Update on AtoKin and Atopic Dermatitis Program

SAN FRANCISCO, California. (December 3, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has re-assessed its atopic dermatitis program and the atopic dermatitis market and has decided to discontinue its AtoKin study in favor of directing resources toward other programs […]

KindredBio to Announce Third Quarter 2014 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, November 13, 2014 SAN FRANCISCO, California. (November 6, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its third quarter 2014 financial results on November […]

Kindred Biosciences Announces Top-Line Results from Pivotal Study of CereKin in Dogs with Osteoarthritis

SAN FRANCISCO, California. (Aug 20, 2014) – Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that its pivotal field study (KB010) of CereKin, an interleukin-1 inhibitor for the control of pain and inflammation associated with osteoarthritis in dogs, did not meet its primary […]

Kindred Biosciences Announces Second Quarter 2014 Financial Results

San Francisco, CA (August 13, 2014) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended June 30, 2014. Conference Call and Webcast at 4:30 p.m. Eastern / 1.30 p.m. Pacific “It is an exciting time for KindredBio as we develop our broad portfolio of drug candidates,” stated Richard Chin, M.D., President […]

KindredBio Schedules Release of 2014 Second Quarter Financial Results and Provides Timeline for Release of CereKin Pivotal Study Data

SAN FRANCISCO, California. (Aug 6, 2014) – Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced the date for release of its 2014 second quarter financial results and provided the timeline for the release of topline data from its multi-center, pivotal clinical trial of CereKin™ […]